

Remarks

The above changes to pages 1 and 36 are intended to comply with paragraph 1 of the Notice. The page attached to this supplemental amendment is intended to comply with paragraph 1 of the Notice.

A clean version of the claims, complying with paragraph 3 of the Notice was submitted to the Examiner by facsimile on November 2, 2001.

If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney at 301-203-6300 (a local call).

Respectfully submitted,

November 20, 2001

PTO Reg. No. 31,712

576 Farmington Road, West Accokeek, MD 20607-9796

Telephone:

301-203-6300

Facsimile:

301-203-9825

Certificate of Mailing by facsimile (37 CFR 1.8): I hereby certify that this supplemental response and clean copy of claims is being transmitted to Examiner DeClowx (fax number 703-746-4982) on 20 November 2001.

William J. Bundren

typed name of person mailing correspondence

Marked replacement paragraph, in compliance with 37 CFR 1.121(b)(1)(iii)

Hybridom2	MUC1 Binding Epitope	Binding to MCF-7 Cells Flow Cytometry (% positive)
Control	•	2%
THI	GVTSAPDTRPAP (Seq. ID No. 1)	72%
TH2	PDTRP (Seq. ID No. 2)	69%
TH3	TSAPDTR (Seq. ID No. 3)	12%
TH4	APDTR (Seq. ID No. 4)	17%
TH5	TSAPDTR (Seq. ID No. 5)	11%
TH6	SAPDTRPA (Seq. ID No. 6)	60%
TH1-TH6 Cocktail	-	55%

In case it is not clearly evident, the parenthetical clauses with the "(Seq. ID No. #)" have been added to all six rows in the middle column.